Upgrade | ARWR Message Board Posts

Arrowhead Pharmaceuticals, Inc.

  ARWR website

ARWR   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  10068 of 10105  at  10/21/2019 11:02:23 AM  by

Manny


Upgrade

Arrowhead price target raised to $54 from $50 at Piper Jaffray Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead to $54 from $50 after the companyhosted an R&D Day on Friday highlighting its TRiM pipeline. The analyst notes that AROANG3 and ARO-APOC3 are advancing to treat diseases characterized by high cholesterol and triglycerides, and anticipates Phase I healthy volunteer SAD data in two late-breaking presentations at AHA on November 18th. Both drugs could begin pivotal studies next year, he adds. Tenthoff reiterates an Overweight on the shares.

Read more at:
https://thefly.com/landingPageNews.php?id=2977752


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 5     Views: 180
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
10069 Re: Upgrade btrane 5 10/21/2019 11:46:54 AM
10072 Re: Upgrade arthurs1 0 10/28/2019 5:18:07 PM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...